Efficacy and safety of bendamustine and ibrutinib in previously untreated patients with Chronic Lymphocytic Leukemia – indirect comparison
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in adults. Optimal approach to the therapy depends of biology of the disease and of the fitness of patients. In young, fit patients therapeutic goal is to achieve complete remission and even negative minimal residual disease. In elderly, frail patients therapy is directed towards palliation. Recently several new drugs have been introduced in the therapy of CLL. Bendamustine is cytotoxic drug with alkylating and purine analogues features, which is widely used in the therapy of indolent lymphomas including CLL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Iga Andrasiak, Justyna Rybka, Wanda Knopinska-Posluszny, Tomasz Wrobel Tags: Review Article Source Type: research

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial
The goal of the present study was to evaluate a novel prospective influenza vaccination strategy in patients with plasma cell disorders. Fifty-one patients were treated with a two dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated led to very high rates of seroprotection against influenza. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Andrew R. Branagan, Eamon Duffy, Randy A. Albrecht, Dennis L. Cooper, Stuart Seropian, Terri L. Parker, Geliang Gan, Fangyong Li, Daniel Zelterman, Chandra Sekhar Boddupalli, Lin Zhang, Rakesh Verma, Thomas M. Ferencz, Madhav V. Dhodapkar Tags: Original Study Source Type: research

Treating Multiple Myeloma Patients with Oral Therapies
Recent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment burden continues to negatively impact the real-world duration of MM therapy, and strategies to limit the adverse impact of treatment on patient quality of life are therefore particularly important.Oral MM therapies include the immunomodulatory drugs lenalidomide, thalidomide and pomalidomide, the alkylating agents melphalan and cyclophosphamide, the histone deacetylase inhibitor panobinostat, the corticosteroids prednisone and dexamethasone, and the proteasome inhibitor ixazomi...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Shaji Kumar, Ravi Vij, Stephen J. Noga, Deborah Berg, Lonnie Brent, Lawrence Dollar, Ajai Chari Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 28, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 28, 2017 Category: Hematology Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17  Abnormalities in B-Cell Acute Lymphoblastic Leukemia
The effect of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Our results showed that MK and CK do not play a predictive role in patients with B-ALL, but further study is required to determine whether specific changes on chromosome 17 might have prognostic value. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2017 Category: Hematology Authors: Priya Khoral, Eshetu G. Atenafu, Kenneth J. Craddock, Aaron Schimmer, Hong Chang Tags: Original Study Source Type: research

Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
We used the Surveillance, Epidemiology, and End Results database to study the incidence and survival of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. We found that the disease incidence varied significantly by age, gender, and race, whereas survival was influenced by age, race, stage, period of diagnosis, and radiotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2017 Category: Hematology Authors: Guru Subramanian Guru Murthy, Mehdi Hamadani, Vijaya Raj Bhatt, Ishwori Dhakal, Paulette Mehta Tags: Original Study Source Type: research

The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia
In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2017 Category: Hematology Authors: Amal S. Alabdulwahab, Hussein G. Elsayed, Mohamed A. Sherisher, Wafa M. Elbjeirami, Nelly Alieldin Tags: Original Study Source Type: research

Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China
One hundred and fifty patients with newly diagnosed Hodgkin's lymphoma at 4 medical centers over a decade were reviewed. General clinical features were comparable to western patients, while therapeutic outcomes were slightly inferior. A new risk model incorporating traditional risk factors and interim imaging response stratified patients into three classes with distinct outcomes, which warrants further validations for better risk-adapted therapeutic strategy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Wen-Yan Yu, Mei Geng, Jie Hao, Mei Chen, Su-Jiang Zhang, Jin Wang, Jian-Qing Mi Tags: Original Study Source Type: research

Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients
To assess whether prolonged use of zoledronic acid (ZA; 4 years) improves outcome in multiple myeloma patients, we performed a clinical trial to compare the effect of 48 and 24 months of treatment. A total of 170 patients were randomly assigned to the 2 groups in the trial. Overall survival was not improved, however, the ZA group showed a reduced number of skeletal events. Thus, we suggest that ZA should be considered to be used for longer duration, in an attempt to improve patient quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Agustin Avil ès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto, Natividad Neri Tags: Original Study Source Type: research

Thoracic Complications in Chronic Lymphocytic  Leukemia
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. Patients with CLL often present with pulmonary symptoms and diagnoses. We performed a retrospective, single-center chart review evaluating all patients with CLL admitted with a thoracic symptom or diagnosis. Although pneumonia is frequent, there are an increasing number of noninfectious complications, which often require lower respiratory tract sampling. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Tags: Original Study Source Type: research

The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia
We examined the long-term clinical outcomes of patients with chronic myeloid leukemia (n  = 41) receiving generic imatinib as first-line (n = 27) and second-line therapy (n = 14) in Bosnia and Herzegovina. Overall survival rates for first-line and second-line generic imatinib were 85% and 100%, respectively. For first-line generic imatinib, complete cytogenetic response was 81%. Gene ric imatinib as second-line therapy does not have deleterious effects on patient outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric Tags: Original Study Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 abnormalities in B-Cell Acute Lymphoid Leukemia
The impact of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities (abnl 17) on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Older age (>60), higher white blood cell count (>30), and abnl 17 were associated with shorter overall survival on univariate analysis, but multivariable analysis only identified older age as an independent poor prognostic actor. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Priya Khoral, Eshetu G. Atenafu, Kenneth J. Craddock, Aaron Schimmer, Hong Chang Tags: Original Study Source Type: research

The Dana Farber Consortium Protocol (DFCP) for the treatment of adolescents and young adults with acute lymphoblastic leukemia: a single institution experience in Saudi Arabia
This retrospective study sought to evaluate the feasibility of using the Dana Farber Consortium Protocol (DFCP) in Saudi adolescents and young adult patients (AYA) with acute lymphoblastic leukemia (ALL). The 3-year leukemia-free survival (LFS) and overall survival (OS) rates were 68% and 70%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism (VTE) was found with the use of enoxaparin prophylaxis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Amal S. Alabdulwahab, Hussein G. Elsayed, Mohamed Atia Sherisher, Wafa M. Elbjeirami, Nelly Alieldin Tags: Original Study Source Type: research

Prolonged Use of Zoledronic ACID ( 4 years) Did Not Improve Outcome In Multiple Myeloma Patients
To assess were prolonged use of zoledronic acid (ZA:4 years) improves outcome in multiple myeloma (MM)patients, we performed a clinical trial, for compared the effect of 48 and 24 months.A total of 170 patients were randomly assigned, to the two groups in the trial.The overall survival was not improved. However ,ZA retain to reduce the number of skeletal events. Thus, we suggested that ZA , will be considered to be employed for longer duration, in attempt to improve patients quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Agustin Avil ès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto, Natividad Neri Tags: Original Study Source Type: research

Thoracic Complications in Chronic Lymphocytic Leukemia (Thoracic Diseases in CLL)
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia. Patients with CLL often present with pulmonary symptoms and diagnoses. We performed a retrospective, single center, chart review evaluating all patients with CLL admitted with a thoracic symptom or diagnosis. Although pneumonia is frequent, there are an increasing number of non-infectious complications, which often require lower respiratory tract sampling. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Tags: Original Study Source Type: research

Clinical features and prognosis analysis of Hodgkin ’s lymphoma: A multicenter retrospective study over a decade of patients in China
Little information of Hodgkin ’s lymphoma (HL) is available in Chinese patients. We analyzed their clinical features, outcome and prognostic factors aiming to establish a new risk model for better risk-adapted therapeutic strategy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Wen-Yan yu, Mei Geng, Jie Hao, Mei Chen, Su-Jiang Zhang, Jin Wang, Jian-Qing Mi Tags: Original Study Source Type: research

Whole Body MR imaging: A Useful Imaging Modality in the Management of Children with Acute Myeloid Leukemia
Children with acute myeloid leukemia suffer from various complications such as chloromas and disseminated infection or inflammation during their illness. As these complications tend to involve everywhere in the body, whole body MR imaging may be a useful tool in children with acute myeloid leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Hee Mang Yoon, Jeong Rye Kim, Ah Young Jung, Young Ah Cho, Ho Joon Im, Jin Seong Lee Tags: Original Study Source Type: research

Systemic Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
We used the SEER database to study the incidence and survival of ALK positive ALCL. We found that the disease incidence varied significantly by age, gender and race, while survival was influenced by age, race, stage, period of diagnosis and radiotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Guru Subramanian Guru Murthy, Mehdi Hamadani, Vijaya Raj Bhatt, Ishwori Dhakal, Paulette Mehta Tags: Original Study Source Type: research

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
We examined the long-term clinical outcomes of CML patients (n=41) receiving generic imatinib as first-line (n=27) and second-line therapy (n=14) in Bosnia and Herzegovina. OS rates for first-line and second-line generic imatinib were 85% vs. 100%, respectively. For first-line generic imatinib, CCyR was 81%. Generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2017 Category: Hematology Source Type: research

The Society of Hematologic Oncology (SOHO): Continuing to Move Forward in the Battle against Hematologic Malignancies
The Society of Hematologic Oncology (SOHO) is an international society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO ’s mission is to promote worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 17, 2017 Category: Hematology Authors: Hagop Kantarjian Tags: Editorial Source Type: research

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy
With the recent progress of allogenic stem cell transplantation (allo-SCT), more patients with acute myeloid leukemia (AML) have access to allo-SCT and mortality has decreased.1 However, 30%-40% of patients relapse, outcome after post-transplant relapse is poor, and most patients do not benefit from salvage chemotherapy. Approximately one-third of these patients harbor Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), which is associated with sensitivity to several tyrosine kinase inhibitors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Sid Selim, Jerome Rey, Aude Charbonnier, Evelyne D'Incan, Bilal Mohty, Didier Blaise, Norbert Vey Tags: Letter to the Editor Source Type: research

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
The purpose of our study was to identify risk factors for the development of posterior reversible encephalopathy syndrome (PRES) after administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH). Of 44 patients receiving DA-EPOCH at our institution, 3 (7%) developed PRES. The patients who developed PRES were more likely to have a pre-existing central nervous system insult, fluid status or electrolytes abnormalities, and hypertension. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Abby E. Floeter, Amila Patel, Melinda Tran, Marc C. Chamberlain, Paul C. Hendrie, Ajay K. Gopal, Ryan D. Cassaday Tags: Original Study Source Type: research

Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients
The aim of the present study was to test the possibility for the usage of the WT1 (Wilms tumor 1) expression level as an additional biomarker for prognosis and minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia with normal karyotype (AML-NK). We found that overexpression of WT1 had a negative effect on treatment outcome. It was a suitable marker for MRD monitoring and a marker for refined risk stratification of AML-NK patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Irena Marjanovic, Teodora Karan-Djurasevic, Milena Ugrin, Marijana Virijevic, Ana Vidovic, Dragica Tomin, Nada Suvajdzic Vukovic, Sonja Pavlovic, Natasa Tosic Tags: Original Study Source Type: research

Comparative study of L-asparaginase-based LOP regimen over CHOP regimen before radiotherapy for stage IIE extranodal nasal type NK/T cell lymphoma : a study of two centers
At present, various L-asparaginase-based regimens were used to treat stage IIE extranodal nasal type NK/T cell lymphoma (ENKTL). This retrospective study analyzed the data of 80 patients to evaluate the efficacy of a new L-asparaginase-based LOP regimen + radiotherapy (RT) protocol over classic CHOP + RT protocol in Guizhou province of China. It shows that protocol is a safe alternative to other protocols reported in the literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Limin Huang, Bin Yuan, Haixia Wu, Hongliang Chu, Yayun Liu, Shuang Wu, Hong Li, He Lu, Hui Chen Tags: Original Study Source Type: research

Treatment of post transplant relapse of FLT3-ITD mutated AML using 5-azacytidine and sorafenib bitherapy
With the recent progress of allogenic stem cell transplantation (allo-SCT), more patients with Acute Myeloid Leukemia (AML) access to allo-SCT and mortality has decreased1. However, 30-40% of patients relapse, outcome after post-transplant relapse is poor and most patients do not benefit from salvage chemotherapy. Approximately one third of these patients harbor FLT3 internal tandem duplication (FLT3-ITD) which is associated with sensitivity to several Tyrosine Kinase Inhibitors (TKI). Sorafenib is a multikinase inhibitor targeting FLT3 and the Raf/ERK/MAP kinase pathway with single agent clinical activity in FLT3 mutated ...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Selim Sid, Rey Jerome, Charbonnier Aude, D ’Incan Evelyne, Mohty Bilal, Blaise Didier, Norbert Vey Tags: Letter to the Editor Source Type: research

Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH chemotherapy
The purpose of our study was to identify risk factors for development of posterior reversible encephalopathy syndrome (PRES) following administration of DA-EPOCH. Out of 44 patients receiving DA-EPOCH at our institution, 3 (7%) were diagnosed with PRES. Patients who developed PRES were more likely to have a preexisting CNS insult, fluid status or electrolytes abnormalities, and hypertension. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Abby E. Floeter, Amila Patel, Melinda Tran, Marc C. Chamberlain, Paul C. Hendrie, Ajay K. Gopal, Ryan D. Cassaday Tags: Original Study Source Type: research

Evidence for Selective Benefit of Sequential Treatment with Hypomethylating agents in Patients with Myelodysplastic Syndrome (MDS)
Hypomethylating agents (HMA) remain the mainstay of treatment in patients with Myelodysplastic Syndrome (MDS). Azacitidine (AZA) is the only agent shown to improve overall survival in higher risk MDS. Sequential use of HMA is a common practice given limited alternatives. The response rate to AZA after Decitabine (DAC) is unknown. To investigate the potential benefit of this approach, we reviewed all cases of sequential HMA treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Susmitha Apuri, Najla Al Ali, Eric Padron, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji Tags: Original Study Source Type: research

Usage of Wilms ’ Tumor 1 (WT1) Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia with Normal Karyotype (AML-NK) Patients
The aim of this study was to test the possibility for the usage of WT1 expression level as an additional biomarker for prognosis and minimal-residual-disease (MRD) monitoring in AML-NK patients. We found that overexpression of WT1 had negative impact on treatment outcome. It was a suitable marker for MRD monitoring, and marker for refined risk stratification of AML-NK patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Irena Marjanovic, Teodora Karan-Djurasevic, Milena Ugrin, Marijana Virijevic, Ana Vidovic, Dragica Tomin, Nada Suvajdzic Vukovic, Sonja Pavlovic, Natasa Tosic Tags: Original Study Source Type: research

Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second line therapy: a multicener prospective observational study
To evaluate quality-of-life (QOL) and adherence to Nilotinib used as a second line therapy in 177 chronic myeloid leukemia patients in chronic phase a multicenter, prospective observational study was conducted. The QOL was very good and adherence to the treatment was high. Study results could be taken into consideration in the process of TKI treatment choice (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Tomasz Sacha, Joanna G óra-Tybor, Ewa Wąsak-Szulkowska, Sławomira Kyrcz-Krzemień, Ewa Mędraś, Rafał Becht, Grażyna Bober, Aneta Kotowska, Joanna Wącław, Andrzej Hellmann Tags: Original Study Source Type: research

More about the risk of Ibrutinib-associated bleeding
Sir (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Ambra Paolini, Valeria Coluccio, Mario Luppi, Marco Marietta Tags: Letter to the Editor Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 31, 2016 Category: Hematology Source Type: research

Myeloma in the Real World: What Is Really Happening?
Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequential therapies, with the goal of prolonging progression-free and overall survival and preserving organ function to enable delivery of further therapy at relapse. (Source: Clinical Lymph...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2016 Category: Hematology Authors: Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Tags: Review Source Type: research

Prognostic Implications of Monosomies in Patients with Multiple Myeloma
This study evaluated the prevalence and prognostic implications of monosomies in 170 Korean patients with multiple myeloma (MM). Monosomies in chromosomes 16, chromosomes 13, TP53 (17p) deletion, and hypodiploidy had adverse prognostic implications in patients with MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2016 Category: Hematology Authors: Sang-Yong Shin, Hyeon-Seok Eom, Ji Yeon Sohn, Hyewon Lee, Boram Park, Jungnam Joo, Ja-Hyun Jang, Mi-Na Lee, Jung Kwon Kim, Sun-Young Kong Tags: Original Study Source Type: research

Myeloma in the Real World: What ’s really happening?
Multiple myeloma (MM) is the second most common haematological malignancy and predominantly a disease of the elderly. In the last two decades a range of new therapeutic options have become available leading to improvements in patient outcomes including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach towards more active management including use of sequential therapies, with the goal to prolong progression-free and overall survival, while preserving organ function to enable delivery of further therapy at relapse. (Source: Clinical Lymphoma, ...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2016 Category: Hematology Authors: Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Tags: Review Article Source Type: research

Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma
Immune cell subsets in the blood of patients with diffuse large B-cell lymphoma before therapy were characterized by flow cytometry, and the levels of various T-cell types and natural killer cells were correlated with the eventual outcomes. High absolute levels of CD4 cells in the blood correlated with better progression-free survival and, to a lesser extent, overall survival, independent of patient age and International Prognostic Index score. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 28, 2016 Category: Hematology Authors: Julia Judd, Essel Dulaimi, Tianyu Li, Michael M. Millenson, Hossein Borghaei, Mitchell R. Smith, Tahseen Al-Saleem Tags: Original Study Source Type: research

Low Level of Blood CD4+ T-Cells Is An Independent Predictor of Inferior Progression Free Survival in Diffuse Large B-Cell Lymphoma
Immune cell subsets in blood of patients with diffuse large B cell lymphoma prior to therapy were characterized by flow cytometry and levels of various T-cell types and NK cells correlated with eventual outcomes. High absolute levels of CD4 cells in blood correlated with better progression free survival, and to a lesser extent overall survival, independent of age and IPI. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 28, 2016 Category: Hematology Authors: Julia Judd, Essel Dulaimi, Tianyu Li, Michael M. Millenson, Hossein Borghaei, Mitchell R. Smith, Tahseen Al-Saleem Tags: Original Study Source Type: research

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age
Autologous hematopoietic cell transplantation has been shown to prolong survival in patients with multiple myeloma; however, adequate data are lacking for patients aged> 70 years and   70 vs.  ≤ 50 years). Our study showed comparable outcomes between these 2 age groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Authors: Binod Dhakal, Ariel Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, Marcello Pasquini, Anita D'Souza, Parameswaran Hari Tags: Original Study Source Type: research

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Impact of Age
Autologous hematopoietic cell transplantation (AHCT) has been shown to prolong survival in patients with multiple myeloma (MM), however adequate data is lacking in patients>70 years and less than 50 years of age. We retrospectively analyzed and compared the outcome of patients between the two age groups (>70 vs. ≤ 50 yrs.). Our study showed comparable outcomes between these two age groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Authors: Binod Dhakal, Ariel Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, Marcello Pasquini, Anita D ’Souza, Parameswaran Hari Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Source Type: research

Acute Leukemia of Ambiguous Lineage in Elderly Patients – Analysis of Survival using Surveillance Epidemiology and End Results-Medicare Database
We used the SEER-Medicare database to study the overall survival and treatment pattern of elderly patients with acute leukemia of ambiguous lineage in United States. Overall survival of this leukemia remains poor, but is improved significantly with chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 22, 2016 Category: Hematology Authors: Guru Subramanian Guru Murthy, Ishwori Dhakal, Jeanette Y. Lee, Paulette Mehta Tags: Original Study Source Type: research

Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era
The standard of care for diffuse large B-cell lymphoma (DLBCL) relapsing after front-line therapy is high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients with relapsed or refractory DLBCL experiencing relapse> 1 year after ASCT had good outcomes. Despite the relative rarity in incidence, a significant risk of relapse of DLBCL after ASCT remains, suggesting the need for continued monitoring because of the possibility of later progression. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Bradley D. Hunter, Megan Herr, Philip J. Meacham, Ferdous Barlaskar, Andrew G. Evans, W. Richard Burack, Jane L. Liesveld, Michael W. Becker, Laurie A. Milner, Louis S. Constine, Sughosh Dhakal, Paul M. Barr, Jonathan W. Friedberg, Carla Casulo Tags: Original Study Source Type: research

Late Relapses following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era
The standard of care for diffuse large B cell lymphoma (DLBCL) relapsing after front line therapy is high dose chemotherapy and autologous stem cell transplant (ASCT). Evidence suggests that early relapses (i.e. within 1 year) following this approach portends exceptionally poor outcomes. However, there are limited data examining relapses>1 year after ASCT for patients with refractory or relapsed DLBCL, particularly in the rituximab era. We sought to examine the impact of early ( ≤1 year) and late (>1 year) relapse following ASCT in a single-institution cohort of patients with relapsed and refractory DLBCL treated ...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Bradley D. Hunter, Megan Herr, Philip J. Meacham, Ferdous Barlaskar, Andrew G. Evans, W. Richard Burack, Jane L. Liesveld, Michael W. Becker, Laurie A. Milner, Louis Constine, Sughosh Dhakal, Paul M. Barr, Jonathan W. Friedberg, Carla Casulo Tags: Original Study Source Type: research

Practical Considerations in Managing Relapsed Multiple Myeloma
Considerable advances have been made in the treatment of relapsed and relapsed/refractory multiple myeloma (RRMM), with numerous novel agents and combination strategies receiving regulatory approvals worldwide over the last several years. An increasing body of phase III data clearly demonstrates increased overall response rates, improved depths of response and more durable responses when a third novel agent is incorporated into Lenalidomide-Dexamethasone and Bortezomib-Dexamethasone platforms, in most cases with acceptable toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Amit Agarwal, Eric Chow, Manisha Bhutani, Peter M. Voorhees, Reed Friend, Saad. Z. Usmani Tags: Review Article Source Type: research

Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis
Several induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). We show that the hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. The combination of tyrosine kinase inhibitors for Philadelphia chromosome-positive (+) patients and rituximab for CD20+ patients were significantly more frequent in the hyper-CVAD arm and might have affected outcomes favorably. There is still a need for large, prospective, randomized studies to establish the best...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Jean El-Cheikh, Imane El Dika, Radwan Massoud, Maya Charafeddine, Rami Mahfouz, Mohamed A. Kharfan-Dabaja, Ali Bazarbachi Tags: Original Study Source Type: research

Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients
Survival for Hodgkin lymphoma has improved over the last 4 decades thanks to reducing the risks of death from primary disease and, expectantly, treatment-related toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Amy Kwan, Nick Chadwick, Barry Hancock Tags: Original Study Source Type: research